StemCell Therapy

Puma Biotechnology Inc (PBYI) was Reiterated by RBC Capital Mkts to Sector Perform while Lowering the Price Target of the company shares to $ 17 from a previous price target of $48 . RBC Capital Mkts advised their Clients and Investors in a research report released on Mar 2, 2017.

Based on several research reports , Shares were Reiterated by RBC Capital Mkts on Mar 2, 2017 to Sector Perform and Lowered the Price Target to $ 17 from a previous price target of $48 .

Several company insiders have filed Insider transactions , on Jan 24, 2017, Steven Lo (Chief Commercial Officer) sold 2,290 shares at $33.24 per share price. According to the SEC, on Jan 24, 2017, Charles R Eyler (officer ) sold 820 shares at $33.24 per share price. On Jan 24, 2017, Richard Paul Bryce (SR VP, CLINICAL RESEARCH & DEV) sold 2,293 shares at $33.24 per share price, according to the Form-4 filing with the securities and exchange commission.

Puma Biotechnology Inc opened for trading at $36.2 and hit $37.6 on the upside on Monday, eventually ending the session at $37.35, with a gain of 3.18% or 1.15 points. The heightened volatility saw the trading volume jump to 9,22,483 shares. Company has a market cap of $1,375 M.

Puma Biotechnology Inc. is a biopharmaceutical company that focuses on the acquisition development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use. It licenses the rights to three drug candidates. It is developing PB272 (neratinib (oral)) for the treatment of patients with human epidermal growth factor receptor type 2 (HER2) positive breast cancer and patients with non-small cell lung cancer breast cancer and other solid tumors that have a HER2 mutation. It is developing PB272 (neratinib (intravenous)) for the treatment of patients with advanced cancer. PB357 is an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors HER1 HER2 and HER4.

See more here:
RBC Capital Mkts Released Sector Perform Rating on Puma Biotechnology Inc (PBYI) - Times Money

This entry was posted on March 6, 2017 at 7:41 am and is filed under Biotechnology. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |